Seeking to outpace the market, investors engage in the art of selecting individual stocks. The right picks can play a pivotal role in boosting your wealth.
The price of Mineralys Therapeutics Inc (NASDAQ: MLYS) closed at $35.71 in the last session, down -1.60% from day before closing price of $36.29. In other words, the price has decreased by -$1.60 from its previous closing price. On the day, 0.89 million shares were traded. MLYS stock price reached its highest trading level at $36.61 during the session, while it also had its lowest trading level at $35.655.
Ratios:
We take a closer look at MLYS’s different ratios to gain a better understanding of the stock. For the most recent quarter (mrq), Quick Ratio is recorded 25.50 and its Current Ratio is at 25.50. In the meantime, Its Debt-to-Equity ratio is 0.00 whereas as Long-Term Debt/Eq ratio is at 0.00.
Upgrades & Downgrades
In the most recent recommendation for this company, Jefferies on June 11, 2025, initiated with a Hold rating and assigned the stock a target price of $15.
On July 10, 2024, H.C. Wainwright started tracking the stock assigning a Buy rating and target price of $30.
On April 02, 2024, Goldman started tracking the stock assigning a Buy rating and target price of $30.Goldman initiated its Buy rating on April 02, 2024, with a $30 target price.
Insider Transactions:
An investor can also benefit from insider trades by learning what management is thinking about the future direction of stock prices. A recent insider transaction in this stock occurred on Jan 02 ’26 when Rodman David Malcom bought 262,752 shares for $35.71 per share.
Slingsby Brian Taylor sold 1,000,000 shares of MLYS for $43,350,000 on Nov 20 ’25. The Director now owns 7,903,838 shares after completing the transaction at $43.35 per share. On Nov 20 ’25, another insider, Catalys Pacific Fund, LP, who serves as the Affiliate of the company, bought 1,000,000 shares for $42.12 each.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, MLYS now has a Market Capitalization of 2826087680 and an Enterprise Value of 2232459776.
Stock Price History:
The Beta on a monthly basis for MLYS is 0.50, which has changed by 1.7363985 over the last 52 weeks, in comparison to a change of 0.14778805 over the same period for the S&P500. Over the past 52 weeks, MLYS has reached a high of $47.65, while it has fallen to a 52-week low of $8.24. The 50-Day Moving Average of the stock is -10.09%, while the 200-Day Moving Average is calculated to be 41.99%.
Shares Statistics:
According to the various share statistics, MLYS traded on average about 1.47M shares per day over the past 3-months and 1557450 shares per day over the past 10 days. A total of 78.97M shares are outstanding, with a floating share count of 56.37M. Insiders hold about 28.77% of the company’s shares, while institutions hold 79.63% stake in the company. Shares short for MLYS as of 1765756800 were 7948340 with a Short Ratio of 5.41, compared to 1763078400 on 6889251. Therefore, it implies a Short% of Shares Outstanding of 7948340 and a Short% of Float of 12.560001000000002.
Earnings Estimates
. The current rating of Mineralys Therapeutics Inc (MLYS) reflects the combined expertise of 7.0 analysts actively engaged in assessing its market performance.The consensus estimate for the next quarter is -$0.54, with high estimates of -$0.44 and low estimates of -$0.67.
Analysts are recommending an EPS of between -$2.13 and -$2.57 for the fiscal current year, implying an average EPS of -$2.4. EPS for the following year is -$2.31, with 6.0 analysts recommending between -$1.74 and -$3.03.
